A Single‐center, Open‐label, Parallel Control Study Comparing the Pharmacokinetics and Safety of a Single Oral Dose of Roflumilast and Its Active Metabolite Roflumilast N‐oxide in Healthy Chinese and Caucasian Volunteers
Author:
Affiliation:
1. Drug Clinical Trial Research Center China‐Japan Friendship Hospital Beijing China
2. Tianjin Chasesun Pharmaceutical Co., Ltd. B01 Entrepreneurship Headquarters Tianjin China
Publisher
Wiley
Subject
Pharmacology (medical),Pharmaceutical Science
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1209
Reference38 articles.
1. Anti‐inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro;Hatzelmann A;J Pharmacol Exp Ther,2001
2. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor;Bundschuh DS;J Pharmacol Exp Ther,2001
3. Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial
4. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
5. Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3